For Research Use Only. Not for use in diagnostic procedures.
Purified human complement component C5. Complement component C5 is unique to the terminal complement pathway. 190 kD C5 protein is comprised of two chains (α 115 kD; ? 75 kD) and is present in plasma at 70 mg/L. Activation of either complement pathway can generate a C5 convertase enzyme capable of cleaving C5 to C5a (a potent anaphylatoxin) and C5b. Together with the other proteins of the terminal pathway, C5b forms the membrane attack complex or MAC.
All Quidel complement components are tested for functional activity in a standard lytic or applicable functional assay and for biochemical purity by SDS-polyacrylamide gel electrophoresis. Please refer to the Certificate of Analysis for lot specific information on functional titer.
Quidel's purified human complement components are useful in a wide variety of immunochemical and research applications. For assistance with a specific protocol, please contact Quidel Technical Support.
References
Nicholson-Weller, Butko, P, Wessels, M. Role of Complement Component C1q in IgG Independent Opsonophagocytosis of Group B Streptococcus, J. Immunol 163:2761-2768, 1999.
Barbashov, S., Wang C. Nicholson-Weller, A. Serum amyloid P component forms a stable complex with human C5b-6, J. Immunol. 158:3830-3835, 1997.
Koski, C., Dashell, S. Sublytic terminal complement complex decreases Po gene expression in schwan cells, J Neurochem 73(6):2321-2330, 1999.
Features & Benefits
| Feature | Benefit |
|---|
Product Specifications
| Product Spec Name | Product Spec Data |
|---|---|
|
Concentration
|
1.0 mg/mL |
|
Volume/vial
|
250 μL/vial |
|
Storage
|
At or below –70°C |
|
Purity
|
> 90% |
|
Buffer
|
PBS |
Ordering Information
| Catalog Number | Kit Size / Case Size |
|---|---|
|
A403
|
250 μL/vial
|
